Alkem Labs gets inspection report from USFDA for Gujarat API facility
New Delhi : Drug firm Alkem Laboratories said it has received establishment inspection report (EIR) from the US health regulator on the closure of its inspection at its API facility at Ankaleshwar in Gujarat.
“The US FDA has issued an establishment an inspection report (EIR) for company's Active Pharmaceutical Ingredient (API) manufacturing facility located at Ankaleshwar, India which was inspected in December, 2016. The inspection has now been closed by the US FDA,” the company said in a filing to BSE.
Alkem Laboratories has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timeline. The USFDA has found the CAPA acceptable.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd